Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phlebotomy followed by peginterferon alfa-2a + ribavirin versus standard peginterferon alfa-2a + ribavirin in treatment-naive HCV genotype 1 patients with elevated ferritin
2006-000504-17Phase 4Completed
- Sponsor
- Heinrich Heine University Düsseldorf
- Start
- Apr 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2a and ribavirin in hepatitis C virus infection (2 arms), sponsored by Heinrich Heine University Düsseldorf. Primary endpoint: Estimated reduction in viral load at 4 weeks after start of antiviral drug therapy. Started Apr 2006; status: completed.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2006-000504-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000504-17.